Kiromic BioPharma logo

Kiromic BioPharmaNASDAQ: KRBP

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

16 October 2020

Next earnings report:

14 November 2024

Last dividends:

N/A

Next dividends:

N/A
$1.70 M
-96%vs. 3y high
5%vs. sector
-vs. 3y high
-vs. sector
-101%vs. 3y high
14%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Mon, 28 Oct 2024 13:34:43 GMT
$1.10+$0.20(+22.21%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

KRBP Latest News

Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
businesswire.com19 September 2024 Sentiment: POSITIVE

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that the University of Arizona Cancer Center (UACC) has been activated as the fifth clinical trial site in the Deltacel-01 Phase 1 trial evaluating Deltacel™ (KB-GDT-01), Kiromic's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. The UACC is one of the 57 NCI-Des.

Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial
businesswire.com09 August 2024 Sentiment: POSITIVE

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports interim results near the completion of Part 1 of its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. Based on data from the five patients evaluated for Progression-Fr.

Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial
businesswire.com06 June 2024 Sentiment: POSITIVE

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable six-month follow-up results from the first patient enrolled in the Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. Scans taken six months post-treatment sho.

Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
businesswire.com20 May 2024 Sentiment: POSITIVE

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that UPMC in Pittsburgh, Pennsylvania has been activated as the fourth clinical trial site in the Deltacel-01 Phase 1 trial evaluating Deltacel™ (KB-GDT-01), Kiromic's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC). UPMC is a world-renowned healthcare system that employs some of the nation's top clinicians and.

Kiromic BioPharma to Present at the OTC Markets' Virtual Life Science Investor Forum on March 7th
Business Wire28 February 2024 Sentiment: POSITIVE

HOUSTON--(BUSINESS WIRE)---- $KRBP #GDT--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that Chief Executive Officer Pietro Bersani, Chief Financial Officer Brian Hungerford and Chief Scientific Officer and Interim Operations Officer Leonardo Mirandola, Ph.D., will participate in the OTC Markets' Life Science Investor Forum in a Fireside Chat format, hosted by VirtualInvestorConferences.com, on March 7th, 2024. Date: March 7, 2024 Time: 11:00 a.m. Eastern time Link: https://bit.l.

What type of business is Kiromic BioPharma?

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

What sector is Kiromic BioPharma in?

Kiromic BioPharma is in the Healthcare sector

What industry is Kiromic BioPharma in?

Kiromic BioPharma is in the Biotechnology industry

What country is Kiromic BioPharma from?

Kiromic BioPharma is headquartered in United States

When did Kiromic BioPharma go public?

Kiromic BioPharma initial public offering (IPO) was on 16 October 2020

What is Kiromic BioPharma website?

https://kiromic.com

Is Kiromic BioPharma in the S&P 500?

No, Kiromic BioPharma is not included in the S&P 500 index

Is Kiromic BioPharma in the NASDAQ 100?

No, Kiromic BioPharma is not included in the NASDAQ 100 index

Is Kiromic BioPharma in the Dow Jones?

No, Kiromic BioPharma is not included in the Dow Jones index

When was Kiromic BioPharma the previous earnings report?

No data

When does Kiromic BioPharma earnings report?

The next expected earnings date for Kiromic BioPharma is 14 November 2024